StockData
Cytek Biosciences, Inc. logo

Cytek Biosciences, Inc. (CTKB) stock

CTKBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/309% below fair value
$5.70+0.07 (+1.24%)

Close on Nov 17, 2026Market cap $740.91MP/E –Yield –

Cytek Biosciences cash

Cash and short-term investments held at the end of each period.

Cytek Biosciences's cash was $73.85M at Jun 30, 2026. For fiscal 2025 it was $90.85M, down 8.0% from the year before. The highest annual figure on record is $364.62M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$90.85M-8.0%
FY2024Dec 31, 2024$98.75M-41.1%
FY2023Dec 31, 2023$167.63M-44.0%
FY2022Dec 31, 2022$299.50M-17.9%
FY2021Dec 31, 2021$364.62M+119.5%
FY2020Dec 31, 2020$166.12M+444.8%
FY2019Dec 31, 2019$30.49M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$73.85M-2.2%
Q1 FY2026Mar 31, 2026$65.67M-31.1%
Q4 FY2025Dec 31, 2025$90.85M-8.0%
Q3 FY2025Sep 30, 2025$93.28M-42.5%
Q2 FY2025Jun 30, 2025$75.47M-57.6%
Q1 FY2025Mar 31, 2025$95.30M-43.7%
Q4 FY2024Dec 31, 2024$98.75M-41.1%
Q3 FY2024Sep 30, 2024$162.30M-0.8%
Q2 FY2024Jun 30, 2024$177.92M+35.3%
Q1 FY2024Mar 31, 2024$169.14M+27.8%
Q4 FY2023Dec 31, 2023$167.63M-44.0%
Q3 FY2023Sep 30, 2023$163.63M-52.1%
Q2 FY2023Jun 30, 2023$131.54M-62.4%
Q1 FY2023Mar 31, 2023$132.39M-63.5%
Q4 FY2022Dec 31, 2022$299.50M-17.9%
Q3 FY2022Sep 30, 2022$341.52M-9.4%
Q2 FY2022Jun 30, 2022$349.89M+118.9%
Q1 FY2022Mar 31, 2022$362.51M+115.0%
Q4 FY2021Dec 31, 2021$364.62M+119.5%
Q3 FY2021Sep 30, 2021$376.77M+960.5%
Q2 FY2021Jun 30, 2021$159.85M+352.5%
Q1 FY2021Mar 31, 2021$168.58M+452.9%
Q4 FY2020Dec 31, 2020$166.12M–
Q3 FY2020Sep 30, 2020$35.53M–
Q2 FY2020Jun 30, 2020$35.32M–
Q4 FY2019Dec 31, 2019$30.49M–

More Cytek Biosciences figures

See a number that looks wrong?